Empagliflozin cost‐effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction
Abstract Aims Empagliflozin, a sodium‐glucose co‐transporter 2 inhibitor, was shown to be effective in patients with heart failure with preserved ejection fraction (HFpEF) in the EMPEROR‐Preserved trial. The present study aims to evaluate the cost‐effectiveness of empagliflozin among Japanese patien...
Gardado en:
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Oxford University Press
2024-02-01
|
| Series: | ESC Heart Failure |
| Assuntos: | |
| Acceso en liña: | https://doi.org/10.1002/ehf2.14565 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|